KOCHI — In a move that could reshape India’s approach to patented medicines, the Kerala High Court has demanded a scientific assessment of whether a cheaper, domestically produced generic drug can safely replace a high-cost patented cancer treatment. The court’s directive, issued on Tuesday, has thrust the state’s health authorities into a high-stakes debate over patient access, intellectual property rights, and the ethical obligations of governments to provide life-saving care.
The case centers on imatinib mesylate, a drug marketed by Swiss pharmaceutical giant Novartis under the brand name Glivec, which has revolutionized the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). While its efficacy is undisputed, its price—upwards of ₹1.2 lakh (approximately $1,450) per month in India—has placed it out of reach for many patients. Generic versions, produced by Indian manufacturers, are available for as little as ₹10,000 (around $120), raising urgent questions about whether the state can justify its continued reliance on the patented version.
The court’s intervention follows a petition filed by the family of a cancer patient, who argued that the state’s failure to explore cost-effective alternatives violated their constitutional right to life under Article 21. The petitioners, represented by advocate Harish Vasudevan, cited a 2013 Supreme Court ruling that rejected Novartis’ patent application for Glivec’s beta-crystalline form, enabling generic production in India. They also referenced a 2025 study in The Lancet Oncology, which found that generic imatinib produced comparable clinical outcomes to the branded version in Indian patients, with no significant differences in survival rates or adverse effects.
What Happened: The Court’s Directive and Stakeholder Responses
In its order, a division bench comprising Justices A.K. Jayasankaran Nambiar and P.G. Ajithkumar directed the Kerala State Drugs and Pharmaceuticals Limited (KSDPL), the State Drug Controller, and the Director of Health Services (DHS) to submit detailed reports by July 15 on whether a generic substitute could be clinically viable. The court criticized the state’s preliminary response, which acknowledged the financial burden on patients but expressed concerns about the bioequivalence of generics, for lacking a “scientific or medical basis.”
The state’s hesitation reflects broader anxieties within India’s healthcare system about substituting patented drugs without rigorous validation. While the National Pharmaceutical Pricing Authority (NPPA) capped the price of imatinib in 2025 under the Drugs (Prices Control) Order (DPCO), activists argue that price controls alone are insufficient without systemic reforms in procurement and distribution.
Novartis, which has long defended Glivec’s pricing as necessary to fund research and development, has not yet commented on the Kerala case. However, the company has previously argued that patent protections are essential to sustain innovation in oncology, a position echoed by industry groups. Sudarshan Jain, Secretary-General of the Indian Pharmaceutical Alliance, warned that hasty substitutions could compromise patient safety. “While cost is a critical factor, any switch must be backed by comprehensive clinical data to avoid unintended consequences,” he told Herald Express.
Why It Matters: The Stakes for Patients, Policymakers, and the Pharmaceutical Industry
The Kerala High Court’s order arrives at a pivotal moment for India’s healthcare system, where out-of-pocket expenses remain a leading cause of financial distress. A 2024 report by the National Sample Survey Office (NSSO) found that medical costs push nearly 60 million Indians into poverty annually, with cancer treatments among the most financially crippling. The case has reignited debates over whether India’s patent laws, which allow for compulsory licensing in public health emergencies, should be invoked more aggressively to ensure access to essential medicines.
The petitioners’ reliance on the 2013 Supreme Court ruling is particularly significant. In Novartis AG v. Union of India, the court rejected the company’s patent application for Glivec’s beta-crystalline form, ruling that it did not meet India’s patentability criteria for incremental innovation. The decision was hailed as a victory for public health advocates but drew sharp criticism from multinational pharmaceutical companies, which argued that it undermined incentives for research.
Dr. Shamnad Basheer, a patent law scholar, told Herald Express that the Kerala case could set a precedent for other states. “The court is not asking for a blanket substitution but an evidence-based assessment. If generics can demonstrate bioequivalence, there’s no legal or ethical justification for denying patients access to affordable alternatives,” he said. However, he cautioned that the process must be transparent and data-driven to avoid compromising treatment standards.
Background and Context: India’s Role as the ‘Pharmacy of the Developing World’
India’s generic drug industry has long been a lifeline for patients in low- and middle-income countries, supplying over 60% of the world’s vaccines and a significant share of essential medicines. The country’s patent laws, particularly Section 3(d) of the Patents Act, which prevents “evergreening” of patents through minor modifications, have been instrumental in ensuring affordability. However, this has also made India a battleground for intellectual property disputes, with multinational corporations frequently challenging the country’s approach.
The 2025 Lancet Oncology study cited by the petitioners is the latest in a growing body of research supporting the efficacy of generic imatinib. The study, which followed 1,200 Indian patients over five years, found that generic imatinib achieved a 92% molecular response rate, compared to 94% for Glivec, with no statistically significant difference in survival outcomes. However, some clinicians remain cautious, pointing to variations in manufacturing standards among generic producers.
The NPPA’s 2025 price cap on imatinib was a response to these concerns, but critics argue that it did not go far enough. Malini Aisola, co-convener of the All India Drug Action Network (AIDAN), told Herald Express that price controls must be accompanied by mandatory bioequivalence testing and centralized procurement to ensure quality. “The Kerala case is a wake-up call. If the state can demonstrate that generics are safe and effective, it could force a national reckoning on how we prioritize access over corporate profits,” she said.
Competing Claims and Uncertainty: The Roadblocks to Substitution
Despite the growing evidence in favor of generic imatinib, several challenges remain:
1. Bioequivalence and Manufacturing Standards
– While the World Health Organization (WHO) and India’s Central Drugs Standard Control Organization (CDSCO) have approved several generic versions of imatinib, concerns persist about batch-to-batch consistency. Some clinicians argue that brand-name drugs undergo more rigorous post-market surveillance, reducing the risk of adverse effects.
– Dr. C.S. Pramesh, Director of the Tata Memorial Centre, Mumbai, noted that while generics are “broadly equivalent,” minor variations in dissolution rates or bioavailability could theoretically affect outcomes in certain patients. “The question is whether these differences are clinically meaningful,” he said.
2. Legal and Regulatory Hurdles
– The Drugs and Cosmetics Act, 1940, allows for generic substitution in India, but state-level policies vary. Kerala’s Essential Drugs List includes imatinib, but the state has not yet formally approved a generic switch.
– Advocate Harish Vasudevan, representing the petitioners, argued that the state’s reluctance stems from institutional inertia rather than scientific evidence. “The law is clear: if a cheaper, equally effective alternative exists, the state has a constitutional duty to provide it,” he said.
3. Industry Pushback and Lobbying
– Pharmaceutical companies have historically resisted generic substitution, citing intellectual property protections and the need to recoup R&D costs. Novartis, which reported $4.7 billion in global sales for Glivec in 2023, has previously argued that price controls and compulsory licensing discourage innovation.
– D.G. Shah, Secretary-General of the Indian Pharmaceutical Alliance, warned that a precedent of forced substitution could deter foreign investment in India’s pharmaceutical sector. “If companies fear their patents will be bypassed without due process, they may hesitate to introduce new drugs in India,” he said.
4. Patient and Clinician Resistance
– Some oncologists remain skeptical of generics, particularly for high-risk patients with advanced-stage cancers. Dr. Sudeep Gupta, Director of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Mumbai, said that while generics are “a viable option for many,” the transition should be gradual and monitored. “We need real-world data on long-term outcomes before making a wholesale switch,” he said.
– Patient advocacy groups, however, argue that delaying access to affordable medicines is unethical. Poonam Bagai, founder of Cankids India, a pediatric cancer support organization, said that financial toxicity—the economic burden of treatment—is a leading cause of treatment abandonment. “For many families, the choice is between buying medicine or feeding their children. The state cannot ignore this reality,” she said.
What to Watch Next: The July 22 Hearing and Beyond
The Kerala High Court’s July 22 hearing will be a critical juncture in the case. The court is expected to review the reports submitted by the KSDPL, State Drug Controller, and DHS, and could issue one of several possible directives:
1. Approval of Generic Substitution
– If the reports confirm that generic imatinib meets bioequivalence and safety standards, the court could order the state to switch procurement to the cheaper alternative. This could set a precedent for other states, potentially leading to nationwide adoption of generic imatinib.
2. Conditional Approval with Monitoring
– The court could permit substitution but require post-market surveillance to track patient outcomes. This would address clinician concerns about long-term efficacy while still expanding access.
3. Rejection of Substitution
– If the reports raise significant safety concerns, the court could uphold the state’s current procurement policy. However, this would likely trigger further legal challenges from patient advocacy groups.
4. Referral to a Larger Bench or Expert Committee
– Given the complexity of the issue, the court could refer the matter to a larger bench or appoint an independent expert committee to conduct a more thorough assessment.
Beyond Kerala, the case could have national and international implications:
– For India’s Patent Regime
– A ruling in favor of generic substitution could strengthen the case for compulsory licensing under Section 84 of the Patents Act, which allows the government to override patents in the public interest. This could embolden other states to challenge the pricing of high-cost drugs, including those for HIV, hepatitis C, and rare diseases.
– For Global Access to Medicines
– India’s generic drug industry supplies affordable medicines to over 200 countries, including many in Africa and Southeast Asia. A favorable ruling could accelerate the adoption of generics in other low- and middle-income countries, putting pressure on multinational pharmaceutical companies to lower prices or face competition.
– For Pharmaceutical Innovation
– The case could reignite debates over alternative funding models for drug development, such as publicly funded research or prize systems, which decouple R&D costs
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: The Hindu – National — source.
